Regeneron Pharmaceuticals, Inc. REGN obtained positive opinion for its pipeline candidate linvoseltamab from the European ...

The positive CHMP opinion is supported by data from the pivotal LINKER-MM1 trial, which evaluated linvoseltamab in adults with R/R MM. Earlier this month, the FDA accepted for review the Biologics ...

Pharmaceuticals announced that the European Medicines Agency’s, EMA, Committee for Medicinal Products for Human Use, CHMP, has ...

Regeneron on Friday said the recommendation covers adults with adults with relapsed and refractory multiple myeloma who have received at least three prior therapies, including a proteasome inhibitor, ...

Regeneron has moved closer to a regulatory filing for its BCMAxCD3 bispecific antibody linvoseltamab, the first of a series of bispecifics that is spearheading its oncology pipeline. New data from ...

The aforementioned therapies and other drugs like Regeneron’s linvoseltamab are all being tested in pivotal trials as second- or third-line therapies. So, GSK’s window of opportunity with ...

FDA decision expected by July 30, 2025TARRYTOWN, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S ...

Introduction: Only in recent years has balloon kyphoplasty gained significance in the treatment of vertebral fractures as an adequate minimally invasive vertebral stabilization technique ...

Discover the power of script logos! Learn from top brands, get expert tips, and create your iconic logo. Elevate your brand identity with our guide. Have you ever stared at a logo and felt… something?

Every use of the Endorser logo requires prior permission. When using the Endorser logo with permission, please strictly adhere to the guidelines regarding its reproduction, display and spacing as ...

Pre-Market: 8:20:02 a.m. EST ...